The NIAID (National Institute of Allergy and Infectious Diseases of the United States) has announced that HVTN 702, a trial for the efficacy of the large-scale HIV vaccine of a candidate for canarypox vaccine, has been suspended because the vaccine It does not prevent HIV.

In an official statement, AVAC, an HIV prevention advocacy group, the trial, also known under the name Uhambo, which started in 2016, stopped after a review scheduled by an independent data monitoring and security committee that showed no significant differences between the arms of the vaccine and the placebo of the trial. The review did not identify security problems. Trial participants are being informed and will remain in the study for follow-up.

“We always expect the efficacy trials to show positive results that lead to new prevention options, and the trial was well conducted and got a response as quickly as possible,” said Mitchell Warren, AVAC executive director, who says it is ” very disappointing “that this candidate vaccine does not work.

HVTN 702 evaluated whether an HIV vaccination regime under investigation is safe, tolerable and effective in preventing HIV infection among 5,400 South African adult men and women between the ages of 18 and 35. The Phase 2b / 3 study, the largest and most advanced HIV vaccine trial to be conducted in South Africa, was adapted from the vaccine strategy tested in the Thai vaccine trial RV144, which showed an infection rate approximately 30% lower among volunteers who received the vaccine against those who received the placebo.

“South Africa has made great contributions to HIV vaccine research and prevention, as researchers, doctors and trial participants,” Warren stressed. “AVAC recognizes the significant contribution of 5,400 volunteers in this test. Their participation makes HIV prevention research possible. AVAC congratulates the essay staff and the global research team for their hard work in carrying out this essay, obtaining a quick response and prioritizing the participants throughout the process. We are glad that the sponsors of this and other research recognize the imperative of working together to sustain the investment, “he stressed.

Parallel to the ongoing active immunization vaccination studies, passive antibody administration is being tested as a prevention strategy in safety and efficacy trials in other trials. These are proof of concept trials in which the monoclonal antibody is widely neutralized in participants every eight weeks. Two of these studies are being carried out in women from seven countries in sub-Saharan Africa, while two others are conducted with men who have sex with men and transgender people who have sex with men in the United States, Peru, Brazil and Switzerland.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies